Hypomethylating agents, such as azacitidine (AZA) and decitabine (DAC), are antimetabolites with a very unique mechanism of action as epigenetic regulator. After being incorporated into the DNA, these inhibit the enzyme, DNA methyltransferase, resulting in the hypomethylation of DNA, and change ...
Decitabineis a DNA methyltransferase inhibitor that targets DNA (cytosine-5)-methyltransferase 1 (DNMT1), interacts with deoxycytidine kinase, and displays antineoplastic, antimetabolite, enzyme-inhibiting, and teratogenic effects. Genes potentially involved in the mechanism of action of this drug include...
The effects of decitabine are likely pleiotropic via additional mechanisms such as the induction of DNA damage.7, 10 Azacitidine gets converted intracellularly to the same active moiety 5-AZA-dCTP prior to incorporation into DNA and thus has a similar mechanism of action to decitabine, but a ...
Besides 5-azacytidine (azacitidine, Vidaza®), 5-aza-2′-deoxycytidine (decitabine, Dacogen®) is the most widely used inhibitor of DNA methylation, which triggers demethylation leading to consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and in vivo. Although anti...
Azacitidine (AZADecitabine (DACHypomethylating agents, such as azacitidine (AZA) and decitabine (DAC), are antimetabolites with a very unique mechanism of action as epigenetic regulator. After being incorporated into the DNA, thesedoi:10.1007/978-981-10-3332-2_19Shinya Sato...